hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06372613 id: LRG&UC briefTitle: Association Between LRG and Endoscopic Remission in Ulcerative Colitis overallStatus: RECRUITING date: 2024-02-25 date: 2024-12-31 date: 2024-12-31 date: 2024-04-18 date: 2024-04-18 name: Showa Inan General Hospital class: OTHER briefSummary: We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which predicts endoscopic remission in ulcerative colitis patients in this study. Colonoscopy with histology is performed when endoscopic remission will be predicted based on serum LRG values, irrespective of symptoms. Serum LRG levels were analyzed by an enzyme-linked immunosorbent assay. conditions: Ulcerative Colitis in Remission studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Endoscopic remission of UC sex: ALL minimumAge: 20 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Showa Inan General Hospital status: RECRUITING city: Komagane country: Japan name: Akira Horiuchi role: CONTACT lat: 35.71657 lon: 137.93745 hasResults: False
nctId: NCT06372600 id: 2023-181 briefTitle: Effect of Extracorporeal Shock Wave Combined With Autologous Platelet-rich Plasma Injection on Rotator Cuff Calcific Tendinitis overallStatus: NOT_YET_RECRUITING date: 2025-06-01 date: 2025-12-31 date: 2026-02-20 date: 2024-04-18 date: 2024-04-18 name: Xiali Xue class: OTHER briefSummary: The purpose of this study is to explore the effect of extracorporeal shock wave combined with autologous platelet-rich plasma injection on the rehabilitation of rotator cuff calcific tendinitis, to provide new treatment methods and evidence for the rehabilitation of rotator cuff calcific tendinitis, and to reduce patients; pain and return to normal life as soon as possible. conditions: Rotator Cuff Tendinitis conditions: Rotator Cuff Tendinosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Extracorporeal shock wave therapy device name: Platelet-rich plasma measure: Visual Analogue Scale,VAS measure: American Shoulder and Elbow Surgeon's Form,ASES measure: the university of California at Los Angeles shoulder rating scale, UCLA measure: The location and size of the calcifications were examined by ultrasound sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06372574 id: GO44669 briefTitle: A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2028-02-01 date: 2028-02-01 date: 2024-04-18 date: 2024-04-18 name: Genentech, Inc. class: INDUSTRY briefSummary: This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A\*02 eligible patients with locally advanced or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive solid tumors. conditions: Refractory Cancer conditions: Recurrent Cancer conditions: Solid Tumor, Adult studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 210 type: ESTIMATED name: RO7617991 name: Tocilizumab measure: Incidence and Severity of Adverse Events measure: Number of Participants with Abnormal Values in Targeted Vital Signs measure: Number of Participants with Abnormal Values in Clinical Laboratory Test Parameters measure: Serum Concentration of RO7617991 at Specific Timepoints measure: Objective Response Rate (ORR), as Determined by the Investigator According to RECIST v1.1 measure: Duration of Response (DOR), as Determined by the Investigator According to RECIST v1.1 measure: Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1 measure: Overall Survival (OS) measure: Prevalence of Anti-Drug Antibodies (ADAs) to RO7617991 at Baseline and Incidence of ADAs to RO7617991 During the Study sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372561 id: Melatonin- vital pulp therapy briefTitle: Comparative Evaluation of Melatonin Versus MTA on Vital Pulp Therapy in Young Permanent First Molars: An in Vivo Study overallStatus: RECRUITING date: 2023-05-20 date: 2024-05-20 date: 2024-06-20 date: 2024-04-18 date: 2024-04-18 name: Suez Canal University class: OTHER briefSummary: The process of dental caries is dynamic and can be either reversible or irreversible depending on the balance between protective and pathologic factors in the oral cavity. Untreated dental caries causes pulpal injury, inflammation, and necrosis. Melatonin plays an essential role in the regulation of bone growth. The actions that melatonin exerts on odontoblasts may be similar to its action on osteoblasts. conditions: Dental Caries in Children conditions: Vital Pulp Therapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 45 type: ESTIMATED name: Mineral trioxide aggregate (dressing material) name: Melatonin (dressing material) measure: Clinically assessment (Modified visual analogue scale) measure: Clinically assessment (Millar's index) measure: Clinically assessment (presence or abscence) measure: Radiographic assessment (using Image J software program) measure: Radiographic assessment (using Image J software program) measure: Radiographic assessment (using Image J software program) measure: Radiographic assessment (using Image J software program) measure: Radiographic assessment (using Image J software program) sex: ALL minimumAge: 6 Years maximumAge: 8 Years stdAges: CHILD facility: Faculty of Medicine, Suez canal university status: RECRUITING city: Ismailia zip: 41522 country: Egypt name: Ismail Dahshan, PHD role: CONTACT phone: 01012715799 email: dahshan1633@gmail.com lat: 30.60427 lon: 32.27225 hasResults: False
nctId: NCT06372548 id: NEADS0004 briefTitle: Rehabilitation Training Games for Children With Amblyopia overallStatus: RECRUITING date: 2023-03-01 date: 2024-06-01 date: 2024-08-01 date: 2024-04-18 date: 2024-04-18 name: Zhu Dian class: OTHER briefSummary: A gamification product was developed to guide children with amblyopia to develop rehabilitation training habits by combining cognitive evaluation theory and occlusion therapy. A randomized controlled trial was conducted to examine the ease of use, acceptability and treatment compliance of the game. conditions: Amblyopia conditions: Amblyopia Occlusion conditions: Child Behavior conditions: Adherence, Treatment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 34 type: ESTIMATED name: Find You! Cure My Animal Friends name: DuoBao Vision Training System measure: 8-Item Morisky Medication Adherence Scale (MMAS-8): measure: User Experience Questionnaire (UEQ) sex: ALL minimumAge: 7 Years maximumAge: 10 Years stdAges: CHILD facility: Shanghai Jiao Tong University status: RECRUITING city: Shanghai state: Shanghai zip: 200240 country: China name: Zhao Liu role: CONTACT phone: +8618901626266 email: hotlz@sjtu.edu.cn lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06372535 id: FujianUTCM-1 briefTitle: Effects of Tai Chi Chuan With Different Doses on Cognitive Function in Elderly Patients With Mild Cognitive Impairment overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-15 date: 2025-09-30 date: 2024-04-18 date: 2024-04-18 name: Lidian Chen class: OTHER name: Peking University Third Hospital briefSummary: To determine the impact of Tai Chi Chuan with different exercise volume on cognitive function in elderly patients with mild cognitive impairment. conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 540 type: ESTIMATED name: Tai Chi Chuan （dose 1） name: Tai Chi Chuan （dose 2） name: Tai Chi Chuan （dose 3） name: Tai Chi Chuan （dose 4） name: Tai Chi Chuan （dose 5） name: Tai Chi Chuan （dose 6） name: Tai Chi Chuan （dose 7） name: Tai Chi Chuan （dose 8） name: Tai Chi Chuan （dose 9） measure: Montreal Cognitive Assessment measure: Montreal Cognitive Assessment measure: Wechsler Memory Scale measure: Digital Symbol test measure: Trial Making Test part B measure: Stroop color word test measure: Boston naming test measure: Rey-Osterrieth complex graphics test measure: Rey Auditory Verbal Learning Test measure: Blood glucose metabolism index measure: Blood lipid metabolism index measure: Functional Magnetic Resonance Imaging measure: Electroencephalogram measure: Heart rate variability measure: Gut microflora measure: Sleep Quality measure: General health sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372522 id: RMB-0517-23 briefTitle: Oxytocin in Multiparous Women overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2027-04 date: 2024-04-18 date: 2024-04-18 name: Rambam Health Care Campus class: OTHER briefSummary: This is a randomized controlled trial investigating whether continuous oxytocin infusion in multiparous women shortens time to delivery, without altering maternal or neonatal outcomes, in augmented deliveries, compared to intermittent infusion. conditions: Pregnancy Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 166 type: ESTIMATED name: Pitocin Injectable Product measure: The rate of women delivering within 24 hours. measure: Length of latent and active phases of labor. measure: The rate of instrumental and caesarean deliveries. measure: chorioamnionitis measure: obstetric anal sphincter injuries (OASIS) measure: hyponatremia measure: post-partum hemorrhage (PPH) measure: neonatal outcome - 1 and 5-minute Apgar score measure: umbilical artery pH measure: NICU admission measure: Women's satisfaction. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372509 id: L2-070 briefTitle: A Proteomic Analysis for Understanding the Link Between Migraine and Cardiovascular Disease acronym: PMCD overallStatus: RECRUITING date: 2024-04-03 date: 2025-10-30 date: 2025-10-30 date: 2024-04-18 date: 2024-04-18 name: Centro Cardiologico Monzino class: OTHER name: IRCCS Policlinico S. Donato briefSummary: This is a multicenter, prospective observational study. Will be collecting data from 90 consecutive patients (aged 25- 60 years ) with and without migraine admitted at our Hospital. Primary aim of the study will be to assess the correlation between migraine and proteomic profiling of plasma and their possible correlation with known cardio and cerebrovascular disease and CV risk factors. conditions: Coronary Artery Disease conditions: Migraine conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 90 type: ESTIMATED measure: Correlation between migraine and proteomic profiling of plasma sex: ALL minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT facility: Centro Cardiologico Monzino status: RECRUITING city: Milano state: Milan zip: 20131 country: Italy name: Daniela Trabattoni, MD role: CONTACT phone: 0258002780 email: daniela.trabattoni@cardiologicomonzino.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06372483 id: VMX-C001-03 id: 2023-507059-32-00 type: CTIS briefTitle: Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral Anticoagulant overallStatus: RECRUITING date: 2024-02-21 date: 2024-09 date: 2024-09 date: 2024-04-18 date: 2024-04-18 name: VarmX B.V. class: INDUSTRY briefSummary: A single centre, double-blind, randomized, placebo-controlled single dose study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of VMX-C001, conducted in two parts:
Part 2: Single dose of VMX-C001 or placebo in combination with a selected factor 10a (FXa) direct oral anticoagulant (DOAC) in healthy older subjects. conditions: Coagulation Disorder studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Placebo controlled, single dose. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Double-blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: VMX-C001 name: Placebo name: Rivaroxaban 20 mg Oral Tablet name: Apixaban 5 mg Oral Tablet name: Edoxaban 60 mg Oral Tablet measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Part 1) measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Part 2) measure: PK of VMX-C001 in plasma - Cmax measure: PK of VMX-C001 in plasma - tmax measure: PK of VMX-C001 in plasma - t1/2 measure: PK of VMX-C001 in plasma - AUC0-last measure: PK of VMX-C001 in plasma - AUC0-inf measure: PK of VMX-C001 in plasma - Lambda z measure: PK of VMX-C001 in plasma - CL measure: PK of VMX-C001 in plasma - Vz measure: DOAC plasma concentrations (Part 2) measure: Change in Prothrombin time (PT) following dosing with VMX-C001 measure: Change in activated partial thromboplastin time (aPTT) following dosing with VMX-C001 measure: Change in D-dimer following dosing with VMX-C001 measure: Change in prothrombin fragments F1 and 2 following dosing with VMX-C001 measure: Change in thrombin generation, measured by lag time, following dosing with VMX-C001 measure: Change in thrombin generation, measured by endogenous thrombin potential, following dosing with VMX-C001 measure: Change in thrombin generation, measured by peak height, following dosing with VMX-C001 measure: Change in thrombin generation, measured by time to peak, following dosing with VMX-C001 measure: Change in thrombin generation, measured by velocity index, following dosing with VMX-C001 measure: Change in thrombin generation, measured by time to tail, following dosing with VMX-C001 measure: Change in diluted prothrombin time (dPT) following dosing with VMX-C001 measure: Change in diluted Russell Viper Venom time (dRVVT) following dosing with VMX-C001 measure: Change in real time activated clotting time (ACT) following dosing with VMX-C001 measure: Antibodies against VMX-C001 in plasma measure: Antibodies against human coagulation FX in plasma sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ICON status: RECRUITING city: Groningen zip: 9728 NZ country: Netherlands name: Salah Hadi, MD role: CONTACT phone: +31 50 8505 798 email: info@iconclinicaltrials.com lat: 53.21917 lon: 6.56667 hasResults: False
nctId: NCT06372470 id: CLM-HTN-005 briefTitle: Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment acronym: OptiZest overallStatus: RECRUITING date: 2024-04-15 date: 2024-08-31 date: 2024-08-31 date: 2024-04-18 date: 2024-04-23 name: Closed Loop Medicine class: INDUSTRY name: Pharmanovia briefSummary: A pragmatic observational proof-of-concept study which aims to determine the feasibility of a remote titration clinic, assisted by home blood pressure monitoring and digital solutions, and assess its impact on real-world outcomes. By incorporating home blood pressure monitoring, the study seeks to offer a promising solution for personalised drug titration and self-management, potentially enhancing patient outcomes while optimising Zestril utilisation conditions: Uncomplicated Hypertension studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Zestril measure: Achieving target Home Blood Pressure measure: Reduction in systolic blood pressure (SBP) measure: Reduction in diastolic blood pressure (DBP) measure: The time to achieve BP Control (BPC) measure: Patient daily adherence to prescribed medication measure: Adherence to collecting data using the electronic BP diary measure: Patients' thoughts and feelings about BP/treatment measure: Discontinuation of Zestril due to unwanted side effects measure: Number and type of spontaneously reported unwanted side effects measure: User experience and feasibility of the blood pressure digital diary sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Norwich Health Centre status: RECRUITING city: Norwich country: United Kingdom name: Serge Engamba, MD role: CONTACT phone: 01603987074 email: serge.engamba@nhs.net name: Marc Buckingham role: CONTACT email: marc.buckingham@nhs.net lat: 52.62783 lon: 1.29834 hasResults: False
nctId: NCT06372444 id: 995725 briefTitle: Mechanisms of Acute Kidney Injury in Severe Infections acronym: PET-AKI overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-03 date: 2026-06-30 date: 2024-04-18 date: 2024-04-19 name: Uppsala University Hospital class: OTHER briefSummary: Renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. For marked water will be used for renal perfusion and a newly developed PET tracer molecule (11C-GW457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. The study is performed in a PET-CT camera where anatomical imaging takes place at the same time as the PET examinations. conditions: Sepsis conditions: AKI - Acute Kidney Injury conditions: Positron Emission Tomography (PET) studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 15 type: ESTIMATED name: Positron emission tomography (PET) measure: Renal perfusion in patients with sepsis and acute kidney injury (AKI) measured by 15O-labeled water in dynamic positron emission tomography (PET) measure: Presence of neutrophil elastase in the kidneys in patients with sepsis and acute kidney injury (AKI) by 11C-GW457427 measured with dynamic positron emission tomography (PET) sex: ALL minimumAge: 30 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372431 id: D1843R00360 briefTitle: PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia acronym: PRIORITY-CKD overallStatus: NOT_YET_RECRUITING date: 2024-04-24 date: 2025-10-31 date: 2025-10-31 date: 2024-04-18 date: 2024-04-18 name: AstraZeneca class: INDUSTRY briefSummary: This study is a multi-centre, non-interventional, observational, prospective study with retrospective analysis. The main purpose of the study is to describe the rate of CKD diagnosis in patients with AH and CKD markers. This study will include 10 000 adult outpatients with arterial hypertension, who have one or more Chronic Kidney Disease laboratory markers (without recorded CKD diagnosis prior to enrolment) and have no diabetes mellitus or chronic heart failure, who are monitored and treated by cardiologists or internal medicine specialists in approximately 50 outpatient sites in about 20 regions in Russia.
This observational study does not provide for any diagnostic and therapeutic procedures other than those used in routine practice. conditions: Arterial Hypertension, Chronic Kidney Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 10000 type: ESTIMATED measure: To describe the rate of CKD diagnosis in patients with AH and CKD markers. measure: To describe demographic and clinical characteristics of patients with AH and CKD markers measure: To describe clinical characteristics of patients with AH and diagnosed CKD during this study (on Visit 1 or Visit 2) and profile of routine therapy before and after CKD diagnosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06372418 id: KEMRI/SERU/CGMR-C/238/4326 briefTitle: Providing Breastfeeding Support After Discharge From Hospital to Improve Growth and Development of Malnourished Infants acronym: IBAMI-2 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-02 date: 2027-02 date: 2024-04-18 date: 2024-04-18 name: University of Oxford class: OTHER briefSummary: The current guidelines used to manage malnutrition among infants aged below 6 months (u6m) recommend that infants admitted to hospital with malnutrition be supported to reestablish exclusive breastfeeding before discharge. Studies have shown that reestablishing exclusive breastfeeding among infants being treated for acute malnutrition is possible. However, follow-up of the infants after discharge has revealed poor growth raising questions about what happens to infant feeding practices after discharge and whether providing breastfeeding support to mothers after discharge would help improve the recovery and growth of their infants.
Providing a package of home-based care with breastfeeding support to mothers of infants u6m recovering from acute malnutrition has the potential to improve the retention of exclusive breastfeeding and lead to enhanced infant growth and survival. To date, no such post-discharge package of care is available in Kenya or other lower and meddle income countries (LMICs). The aim of this study is to apply participatory, qualitative and quantitative approaches to develop and evaluate the impact of a post-discharge package of care on the growth and development of acutely ill malnourished infants after discharge from hospital. conditions: Malnutrition, Infant conditions: Breastfeeding, Exclusive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Control Trial:
Participants will be randomized to either receive Breastfeeding support intervention (BFSI) or standard of care. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Fieldworkers collecting endpoint data at 6 months of age will be blinded to group allocation to avoid any bias subject to knowledge of group allocation. whoMasked: OUTCOMES_ASSESSOR count: 250 type: ESTIMATED name: Breastfeeding peer support intervention name: Standard Care measure: Weight gain measure: Morbidity measure: Mortality sex: ALL minimumAge: 4 Weeks maximumAge: 12 Weeks stdAges: CHILD hasResults: False